Skip to the page

Data / Form D filings / Topaz Biosciences, Inc.

Topaz Biosciences, Inc.: Form D filing

Topaz Biosciences, Inc., a biotechnology company in Emeryville, CA, filed a Form D with the SEC in 2025. The latest, on March 25, 2025, reports $1.4 million sold of a $3.2 million offering to 8 investors.

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

Company details from the filing

Address
1250 45th Street, Suite 320, Emeryville, CA, 94608
Phone
(415) 572-3901
Industry
Biotechnology
Entity type
Corporation
Incorporated in
Delaware
Year incorporated
2022
Revenue range
Decline to Disclose
Exemptions claimed
Rule 506(b)
SEC identifier (CIK)
2062605

Form D filings

FiledTypeOfferingSoldRemainingInvestorsFirst saleFiling
Mar 25, 2025New notice$3,159,994$1,434,996$1,724,9988Mar 11, 2025sec.gov

Executive officers and directors named in the filing

NameRoleNote in the filing
Oliver LiuExecutive Officer, Director
Caroline HadfieldExecutive Officer
Jennifer ShockExecutive Officer, Director
Teresa ShockDirector

Other biotechnology companies in California that filed recently

Every Form D from the week of Mar 24, 2025 · All recent filings in California · All recent Biotechnology filings

Read from SEC EDGAR. Amount sold is what Topaz Biosciences, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.